Search Results - "Sonpavde, Guru P"

Vaccine approaches to treat urothelial cancer by Giudice, Giulia Claire, Sonpavde, Guru P

“…Bladder cancer (BC) accounts for about 4% of all malignancies. Non-muscle-invasive BC, 75% of cases, is treated with transurethral resection and adjuvant…”
Get full text

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma by Sonpavde, Guru P., Mariani, Luigi, Lo Vullo, Salvatore, Raggi, Daniele, Giannatempo, Patrizia, Bamias, Aristotle, Crabb, Simon J., Bellmunt, Joaquim, Yu, Evan Y., Niegisch, Guenter, Vaishampayan, Ulka N., Theodore, Christine, Berthold, Dominik R., Srinivas, Sandy, Sridhar, Srikala S., Plimack, Elizabeth R., Rosenberg, Jonathan E., Powles, Thomas, Galsky, Matthew D., Necchi, Andrea

“…We evaluated the impact of the number of cycles of platinum based, first line chemotherapy (fewer than 6 cycles vs the conventional 6 cycles or more) on the…”
Get full text

Trans-ethnic variation in germline variants of patients with renal cell carcinoma by Abou Alaiwi, Sarah, Nassar, Amin H., Adib, Elio, Groha, Stefan M., Akl, Elie W., McGregor, Bradley A., Esplin, Edward D., Yang, Shan, Hatchell, Kathryn, Fusaro, Vincent, Nielsen, Sarah, Kwiatkowski, David J., Sonpavde, Guru P., Pomerantz, Mark, Garber, Judy E., Freedman, Matthew L., Rana, Huma Q., Gusev, Alexander, Choueiri, Toni K.

“…Prior studies of the renal cell carcinoma (RCC) germline landscape investigated predominantly patients of European ancestry. We examine the frequency of…”
Get full text

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma by Mossanen, Matthew, MD, Chang, Steven L., MD, MS, Kimm, Simon, MD, Sonpavde, Guru P., MD, Kibel, Adam S., MD

“…Please note, the synopsis was used from your supplied original manuscript, and not the accompanying abstract, per journal style: This article discusses current…”
Get full text

Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer by Eich, Marie-Lisa, Rodriguez Pena, Maria Del Carmen, Chandrashekar, Darshan Shimoga, Chaux, Alcides, Agarwal, Sumit, Gordetsky, Jennifer B., Ferguson, James E., Sonpavde, Guru P., Netto, George J., Varambally, Sooryanarayana

“…Cancer cells utilize vitamin folate to fulfill their excessive demand for nucleotides and amino acids. Dihydrofolate reductase (DHFR), an enzyme involved in…”
Get full text

Clinical outcomes and patterns of population‐based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database by Dursun, Furkan, Lim, Kelvin, Svatek, Robert S., Xu, Jiaqiong, El‐Zaatari, Ziad M., Wenker, Evan P., Klaassen, Zachary W., Mansour, Ahmed M., Muhammad, Taliah, Efstathiou, Eleni, Sonpavde, Guru P., Wallis, Christopher J. D., Satkunasivam, Raj

“…Background Given the low incidence of urachal carcinoma of the bladder (UCB), there is limited published data from contemporary population‐based cohorts. This…”
Get full text

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era by Fletcher, Sean A., Harmouch, Sabrina S., Krimphove, Marieke J., Cole, Alexander P., Berg, Sebastian, Gild, Philipp, Preston, Mark A., Sonpavde, Guru P., Kibel, Adam S., Sun, Maxine, Choueiri, Toni K., Trinh, Quoc-Dien

“…Introduction Muscle-invasive bladder cancer (MIBC) is an aggressive disease for which treatment strategies are continuously evolving. We characterized trends…”
Get full text

Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint by Tripathi, Abhishek, MacDougall, Kira, Sonpavde, Guru P.

“…Platinum-based chemotherapy has long been the backbone of treatment for urothelial carcinoma. Immune checkpoint inhibitors have revolutionized the treatment…”
Get full text

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma by Powles, Thomas, Rosenberg, Jonathan E, Sonpavde, Guru P, Loriot, Yohann, Durán, Ignacio, Lee, Jae-Lyun, Matsubara, Nobuaki, Vulsteke, Christof, Castellano, Daniel, Wu, Chunzhang, Campbell, Mary, Matsangou, Maria, Petrylak, Daniel P

“…Patients who had had a relapse after receiving platinum-containing chemotherapy and a PD-1 or PD-L1 immune checkpoint inhibitor were assigned to receive…”
Get full text

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma by Adib, Elio, El‐Zarif, Talal, Jain, Rohit K., Skelton, William P., Freeman, Dory, Curran, Catherine, Akl, Elie W., Nassar, Amin H., Ravi, Praful, Mantia, Charlene, Kwiatkowski, David J., Choueiri, Toni K., Sonpavde, Guru P.

“…Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved…”
Get full text

Editorial Comment on “Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey” by Giudice, Giulia Claire, Sonpavde, Guru P.

Get full text

Management of Bladder Cancer: The First Inning of a New Era of Rapid Advances by Sonpavde, Guru P.

Get full text

Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials by Sonpavde, Guru P, Grivas, Petros, Lin, Yushun, Hennessy, Daniel, Hunt, Jay D

“…Trial-level meta-analysis to investigate differences in immune-related adverse event (irAE) profiles between anti-PD-1/PD-L1 antibodies. Data analyzed from…”
Get full text

Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas by Sonpavde, Guru P, Mouw, Kent W, Mossanen, Matthew

“…Journal of Clinical Oncology,…”
Get full text

Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable? by Brown, Jason R., Sonpavde, Guru P., Calaway, Adam, Barata, Pedro C.

Get full text

The evolving treatment landscape of metastatic urothelial cancer by Roviello, Giandomenico, Santoni, Matteo, Sonpavde, Guru P., Catalano, Martina

“…Cisplatin-based chemotherapy is currently the first-line standard of care for patients with metastatic urothelial cancer (mUC); however, up to 50% of patients…”
Get full text

New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma by McGregor, Bradley A, Sonpavde, Guru P

“…Genomic alterations in penile squamous cell carcinoma (PSCC) appear similar to squamous cell carcinomas of the head and neck and esophagus but not lung, skin,…”
Get full text

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies by McGregor, Bradley Alexander, Campbell, Matthew T., Xie, Wanling, Farah, Subrina, Bilen, Mehmet A., Schmidt, Andrew L., Sonpavde, Guru P., Kilbridge, Kerry L., Choudhury, Atish D., Mortazavi, Amir, Shah, Amishi Y., Venkatesan, Aradhana M., Bubley, Glenn J., Siefker‐Radtke, Arlene O., McKay, Rana R., Choueiri, Toni K.

“…Background In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare…”
Get full text

Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? by Azizi, Mounsif, Aydin, Ahmet M, Hajiran, Ali, Lai, Andrew, Kumar, Ambuj, Peyton, Charles C, Minhas, Suks, Sonpavde, Guru P, Chahoud, Jad, Pagliaro, Lance C, Necchi, Andrea, Spiess, Philippe E

“…Neoadjuvant chemotherapy is a recommended treatment for patients with penile cancer with bulky inguinal lymphadenopathy or unresectable primary tumors,…”
Get full text

Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel by Kapur, Neeraj, Mir, Hina, Sonpavde, Guru P., Jain, Sanjay, Bae, Sejong, Lillard, James W., Singh, Shailesh

“…Molecular reprogramming in response to chemotherapeutics leads to poor therapeutic outcomes for prostate cancer (PCa). In this study, we demonstrated that…”
Get full text